We are a biotechnology company pioneering the development of engineered IgM antibodies for the treatment of cancer patients. IgM antibodies have inherent properties that we believe may enable them to improve upon the efficacy and safety of IgG antibodies in multiple therapeutic applications.

We have created a proprietary IgM antibody technology platform that we believe is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Our lead product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3, and we plan to initiate a Phase 1 clinical trial for the treatment of relapsed/refractory B cell Non-Hodgkin’s lymphoma (NHL) patients in 2019. Our second product candidate is expected to be an IgM antibody targeting Death Receptor 5 (DR5).

IgM antibodies have 10 binding units compared to 2 for IgG antibodies. This inherent biological advantage enables:

  • Stronger binding to cell surface targets, including those with low expression levels, which may result in better and more complete targeting of cancer cells;
  • Stronger binding to difficult targets, such as tumor associated carbohydrates and glycosylated proteins, which has the potential to expand the range of addressable cancer targets;
  • Greater ability to cross-link cell surface receptors, which may significantly enhance cellular signaling for killing cancer cells or stimulating T cells; and
  • Substantially greater ability to utilize the complement dependent cytotoxicity (CDC) mechanism of killing targeted cells, which kills cancer cells without requiring the presence of immune cells.

We believe that we have the most advanced research and development program focused on engineered therapeutic IgM antibodies. We have created a portfolio of patents and patent applications, know-how and trade secrets directed to our platform technology, product candidates and manufacturing capabilities, and we retain worldwide commercial rights to all of our product candidates and intellectual property.

IGM is a well-funded company with a team of approximately 40 scientists at our headquarters in Mountain View, California. We are growing quickly, and we are looking to add motivated individuals who will be as passionate about our mission as we are.  Join Us.

Contact Us

IGM Biosciences, Inc.
325 East Middlefield Road
Mountain View, CA 94043
(650) 965-7873